Cinctive Capital Management LP Purchases Shares of 61,567 DaVita Inc. (NYSE:DVA)

Cinctive Capital Management LP acquired a new stake in DaVita Inc. (NYSE:DVA) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 61,567 shares of the company’s stock, valued at approximately $10,093,000. Cinctive Capital Management LP owned 0.08% of DaVita as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in DaVita by 1.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,759 shares of the company’s stock worth $776,000 after acquiring an additional 70 shares during the period. Wedmont Private Capital boosted its stake in shares of DaVita by 4.4% during the 3rd quarter. Wedmont Private Capital now owns 1,776 shares of the company’s stock valued at $280,000 after buying an additional 75 shares during the period. Blue Trust Inc. grew its holdings in shares of DaVita by 58.6% during the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after acquiring an additional 78 shares in the last quarter. First Trust Direct Indexing L.P. raised its holdings in shares of DaVita by 2.9% during the third quarter. First Trust Direct Indexing L.P. now owns 3,051 shares of the company’s stock worth $500,000 after acquiring an additional 86 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its position in DaVita by 0.3% during the third quarter. Nisa Investment Advisors LLC now owns 36,820 shares of the company’s stock valued at $6,036,000 after purchasing an additional 126 shares during the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Price Performance

Shares of DaVita stock opened at $166.17 on Monday. DaVita Inc. has a 1-year low of $99.18 and a 1-year high of $169.51. The firm has a fifty day simple moving average of $158.57 and a 200-day simple moving average of $149.39. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. The stock has a market capitalization of $13.63 billion, a price-to-earnings ratio of 17.93, a PEG ratio of 0.94 and a beta of 0.89.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The business had revenue of $3.26 billion during the quarter, compared to the consensus estimate of $3.25 billion. During the same quarter in the previous year, the firm posted $2.85 earnings per share. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. On average, sell-side analysts expect that DaVita Inc. will post 9.71 earnings per share for the current year.

Insider Buying and Selling

In other DaVita news, CEO Javier Rodriguez sold 9,881 shares of the firm’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $162.85, for a total value of $1,609,120.85. Following the sale, the chief executive officer now directly owns 887,835 shares in the company, valued at $144,583,929.75. This trade represents a 1.10 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 2.00% of the stock is currently owned by insiders.

Analysts Set New Price Targets

DVA has been the subject of a number of recent research reports. Truist Financial raised their price target on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. Bank of America boosted their target price on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. UBS Group raised their price target on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Finally, Barclays lifted their price objective on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, DaVita currently has a consensus rating of “Hold” and an average target price of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.